Antibiotic and anti-inflammatory therapies for cystic fibrosis

Cold Spring Harbor Perspectives in Medicine

Volumn 3, Issue 10, 2013, Pages

  Chmiel, James F ^a   Konstan, Michael W ^a   Elborn, J Stuart ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CORTICOSTEROID; CYTOKINE; IBUPROFEN; ICOSANOID; PROTEINASE INHIBITOR;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; CELL COMMUNICATION; CHRONIC BRONCHITIS; CYSTIC FIBROSIS; DISEASE ERADICATION; DRUG ANTAGONISM; DRUG EFFECT; FORECASTING; HUMAN; LIFE EXPECTANCY; METHODOLOGY; RESPIRATORY TRACT INFECTION; REVIEW;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTIOXIDANTS; BACTERIAL INFECTIONS; BRONCHITIS, CHRONIC; CELL COMMUNICATION; CYSTIC FIBROSIS; CYTOKINES; DISEASE ERADICATION; EICOSANOIDS; FORECASTING; HUMANS; IBUPROFEN; LIFE EXPECTANCY; PROTEASE INHIBITORS; RESPIRATORY TRACT INFECTIONS;

EID: 84885040441     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a009779     Document Type: Article

References (107)

1. Aldámiz-Echevarría L, Prieto JA, Andrade F, Elorz J, Sojo A, Lage S, Sanjurjo P, Vázquez C, Rodríguez-Soriano J. 2009. Persistence of essential fatty acid deficiency in cystic fi-brosis despite nutritional therapy. Pediatr Res 66: 585-589.
2. Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olin-sky A, Phelan PD. 1995. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fi-brosis. BMJ 310: 1571-1572.
3. Armstrong DS, Grimwood K, Carlin JB, Armstrong DS, Grimwood K, Carlin JB, Carzino R, Gutièrrez JP, Hull J, Olinsky A, et al. 1997. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 156: 1197-1204.
4. Auerbach HS, Williams M, Kirkpatrick JA, Colten HR. 1985. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 2: 686-688.
5. Balfour-Lynn IM, Laverty A, Dinwiddie R. 1996. Reduced upper airway nitric oxide in cystic fibrosis. Arch Dis Child 75: 319-322.
6. Balfour-Lynn IM, Lees B, Hall P, Phillips G, Khan M, Fla-ther M, Elborn JS, CF WISE (Withdrawal of Inhaled Steroids Evaluation) Investigators. 2006. Multicenter randomized controlled trial of withdrawal of inhaled cor-ticosteroids in cystic fibrosis. Am J Respir Crit Care Med 173: 1356-1362.
7. Ballmann M, Junge S, von der Hardt H. 2003. Low-dose methotrexate for advanced pulmonarydiseasein patients with cystic fibrosis. Respir Med 97: 498-500.
8. Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R. 1995. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 20: 63-70.
9. Beharry S, Ackerley C, Corey M, Kent G, Heng YM, Chris-tensen H, Luk C, Yantiss RK, Nasser IA, Zaman M, et al. 2007. Long-term docosahexaenoic acid therapy in a con- genic murine model of cystic fibrosis. Am J Physiol Gastrointest Liver Physiol 292: G839-G848.
10. Berger M, Konstan MW, Hilliard JB. 1995. Aerosolized prolastin (a1-protease inhibitor) in CF. Pediatr Pulmonol 20: 421.
11. Bhal GK, Maguire SA, Bowler IM. 2001. Use of cyclosporin A as a steroid sparing agent in cystic fibrosis. Arch Dis Child 84: 89.
12. Bilton D, Elborn S, Conway S, Edgar J, Redmond A. 1999. Phase II trial to assess the clinical efficacy of transgenic a-1-antitrypsin (tg-hAAT) as an effective treatment of cystic fibrosis. Pediatr Pulmonol 28 (Suppl 19): 246.
13. Birrer P, McElvaney NG, Rüdeberg A, Sommer CW, Liechti-Gallati S, Kraemer R, Hubbard R, Crystal RG. 1994. Pro-tease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 150: 207-213.
14. Bishop C, Hudson VM, Hilton SC, Wilde C. 2005. A pilot study of the effects of inhaled buffered reduced glutathi-one on the clinical status of patients with cystic fibrosis. Chest 127: 308-317.
15. Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hil-liard JB, Ghnaim H, Berger M. 1995a. Inflammatory cy-tokines in cystic fibrosis lungs. Am J Respir Crit Care Med 152: 2111-2118.
16. Bonfield TL, Konstan MW, Burfeind P, Panuska JR, Hilli-ard JB, Berger M. 1995b. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol 13: 257-261.
17. Bonfield TL, Konstan MW, Berger M. 1999. Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 104: 72-78.
18. Chen J, Kinter M, Shank S, Cotton C, Kelley TJ, Ziady AG. 2008. Dysfunction of Nrf-2 in CFepithelia leads to excess intracellular H2O2 and inflammatory cytokine produc tion. PLoS ONE 3: e3367.
19. Chmiel JF, Davis PB. 2003. State of the art: Why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? Respir Res 4: 8-21.
20. Chmiel JF, Konstan MW, Knesebeck JE, Hilliard JB, Bon-field TL, Dawson DV, Berger M. 1999. IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice. Am J Respir Crit Care Med 160: 2040-2047.
21. Chmiel JF, Konstan MW, Berger M. 2002a. The role of inflammation in the pathophysiology of CF lung disease. Clin Review Allergy Immunol 23: 5-27.
22. Chmiel JF, Konstan MW, Saadane A, Krenicky JE, Lester Kirchner H, Berger M. 2002b. Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice. Am J Respir Crit Care Med 165: 1176-1181.
23. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. 2008. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 178: 814-821.
24. Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. 2010. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 303: 2386-2392.
25. Davis PB, Drumm M, Konstan MW. 1996. Cystic fibrosis. State of the art. Am J Resp Crit Care Med 154: 1229-1256.
26. Davis PB, Gupta S, Eastman J, Konstan MW. 2003. Inhibition of proinflammatory cytokine production by PPARg agonists in airway epithelial cells. Pediatr Pulmonol 36 (Suppl 25): 268-269.
27. De Boeck K, Vermeulen F, Wanyama S, Thomas M, Members of the Belgian CF Registry. 2011. Inhaled corticoste-roids and lower lung function decline in young children with cystic fibrosis. Eur Respir J 37: 1091-1095.
28. Döring G, Flume P, Heijerman H, Elborn JS, Consensus Study Group. 2012. Treatment of lung infection in patients with cystic fibrosis: Current and future strategies. J Cyst Fibros 2012 11: 461-479.
29. Dubin PJ, Kolls JK. 2007. IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol 292: L519-L528.
30. Dubin PJ, McAllister F, Kolls JK. 2007. Is cystic fibrosis a TH17 disease? Inflamm Res 56: 221-227.
31. Dunzendorfer S, Rothbucher D, Schratzberger P, Reinisch N, Kahler CM, Wiedermann CJ. 1997. Mevalonate-de-pendent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Circ Res 81: 963-969.
32. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV. 1995. A multicenter study of alternate-day prednisone therapy in patientswith cysticfibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 126: 515-523.
33. Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifilieff A. 2003. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neu-trophilia: IL-15 as a possible trigger. J Immunol 170: 2106-2112.
34. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogay-zel PJ Jr, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, et al. 2007. Cystic fibrosis pulmonary guidelines. Am J Respir Crit Care Med 176: 957-969.
35. 2/2 mice. Proc Natl Acad Sci 96: 13995-14000.
36. 2/2 mice and the effect of docosahexaenoic acid. J Appl Physiol 92: 2169-2176.
37. Grasemann H, Michler E, Wallot M, Ratjen F. 1997. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol 24: 173-177.
38. Grasemann H, Schwiertz R, Matthiesen S, Racke K, Ratjen F. 2005a. Increased arginase activity in cystic fibrosis airways. Am J Respir Crit Care Med 172: 1523-1528.
39. Grasemann H, Grasemann C, Kurtz F, Tietze-Schillings G, Vester U, Ratjen F. 2005b. Oral L-arginine supplementation in cystic fibrosis patients: A placebo-controlled study. Eur Respir J 25: 62-68.
40. Griese M, Latzin P, Kappler M, Weckerle K, Heinzlmaier T, Bernhardt T, Hartl D. 2007. a1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 29: 240-250.
41. Grimbert D, Vecellio L, Delépine P, Attucci S, Boissinot E, Poncin A, Gauthier F, Valat C, Saudubray F, Antonioz P, et al. 2003. Characteristics of EPI-hNE4 aerosol: A new elastase inhibitor for treatment of cystic fibrosis. J Aerosol Med 16: 121-129.
42. Hartl D, Starosta V, Maier K, Beck-Speier I, Rebhan C, Becker BF, Latzin P, Fischer R, Ratjen F, Huber RM, et al. 2005. Inhaled glutathione decreases PGE2 and increases lymphocytes in cystic fibrosis lungs. Free Radic Biol Med 39: 463-472.
43. Hopkins N, Gunning Y, O'Croinin DF, Laffey JG, Mc-Loughlin P. 2006. Anti-inflammatory effect of augmented nitric oxide production in chronic lung infection. J Pathol 209: 198-205.
44. Hull J, Vervaart P, Grimwood K, Phelan P. 1997. Pulmonary oxidative stress response in young children with cystic fibrosis. Thorax 52: 557-560.
45. Jaradat MS, Wongsud B, Phornchirasilp S, Rangwala SM, Shams G, Sutton M, Romstedt KJ, Noonan DJ, Feller DR. 2001. Activation of peroxisome proliferators-activated receptor isoforms and inhibition of prostaglandin H2 synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol 62: 1587-1595.
46. Kelley TJ, Drumm ML. 1998. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest 102: 1200-1207.
47. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. 1995. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151: 1075-1082.
48. Kirchner KK, Wagener JS, Khan TZ, Copenhaver SC, Accurso FJ. 1996. Increased DNA levels in bronchoalveo-lar lavage fluid obtained from infants with cystic fibrosis. Am J Respir Crit Care Med 154: 1426-1429.
49. Konstan MW. 2008. Ibuprofen therapy for cystic fibrosis lung disease: Revisited. Curr Opin Pulm Med 14: 567-573.
50. Konstan MW, Berger M. 1997. Current understanding of the inflammatory process in cystic fibrosis-Onset and etiology. Pediatr Pulmonol 24: 137-142.
51. Konstan MW, Walenga RW, Hilliard KA, Hilliard JB. 1993. Leukotriene B4 is markedly elevated in the epithelial lining fluidof patients with cystic fibrosis. Am Rev Respir Dis 148: 896-901.
52. Konstan MW, Hilliard KA, Norvell TM, Berger M. 1994. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 150: 448-454.
53. Konstan MW, Byard PJ, Hoppel CL, Davis PB. 1995. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 332: 848-854.
54. Konstan MW, Krenicky JE, Finney MR, Kirchner HL, Hilliard KA, Hilliard JB, Davis PB, Hoppel CL. 2003. Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis. J Pharmacol Exp Ther 306: 1086-1091.
55. Konstan MW, Doring G, Lands LC, Hilliard KA, Koker P, Bhattacharya S, Staab A, Hamilton AL. 2005. Results of a phase II clinical trial of BIIL 284 BS (a LTB4 receptor antagonist) for the treatment of CF lung disease. Pediatr Pulmonol 40 (Suppl 28): 125-127.
56. Konstan MW, Schluchter MD, Xue W, Davis PB. 2007. Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 176: 1084-1089.
57. Konstan M, Krenicky J, Hilliard K, Hilliard J. 2009. A pilot study evaluating the effect of pioglitazone, simvastatin, and ibuprofen on neutrophil migration in vivo in healthy subjects. Pediatr Pulmonol 44 (Suppl 32): 289-290.
58. Konstan MW, Geller DE, Minić P, Brockhaus F, Zhang J, Angyalosi G. 2011. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. Pediatr Pulmonol 46: 230-238.
59. Kraynack NC, Corey DA, Elmer HL, Kelley TJ. 2002. Mechanisms of NOS2 regulation by Rho GTPase signaling in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 283: L604-L611.
60. Kraynack NC, Chmiel JF, Xue W, Schluchter MD, Gibson RL, Kelley TJ, Hilliard JB, Konstan MW. 2008. Effect of simvastatin on exhaled nitric oxide and inflammatory markers in sputum in patients with cystic fibrosis. Pediatr Pulmonol 43 (Suppl 31): 300.
61. Lai H-C, FitzSimmons SC, Allen DB, Kosorok MR, Ro-senstein BJ, Campbell PW, Farrell PM. 2000. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med 342: 851-859.
62. Lands L, Stanojevic S. 2007. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst Rev 17: CD001505.
63. Lands LC, Milner R, Cantin AM, Manson D, Corey M. 2007. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 151: 228-230.
64. Lazaar AL, Sweeney LE, MacDonald AJ, Alexis NE, Chen C, Tal-Singer R. 2011. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol 72: 282-293.
65. Linsdell P, Hanrahan JW. 1998. Glutathione permeability of CFTR. Am J Physiol 275 (Pt 1): C323-C326.
66. LiPuma J. 2010. The changing microbial epidemiology in CF. Clin Microbiol Rev 23: 299-323.
67. LiPuma J. 2012. The new microbiology of cystic fibrosis: It takes a community. Thorax 67: 851-852.
68. McAllister F, Henry A, Kreindler JL, Dubin PJ, Ulrich L, Steele C, Finder JD, Pilewski JM, Carreno BM, Goldman SJ, et al. 2005. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth related oncogene-a and granulocyte colony-stimulating factor in bronchial epithelium: Implications for airway inflammation in cystic fibrosis. J Immunol 175: 404-412.
69. McElvaney NG, Hubbard RC, Birrer P, Chernick MS, Caplan DB, Frank MM, Crystal RG. 1991. Aerosol a1-antitrypsin treatment for cystic fibrosis. Lancet 337: 392-394.
70. McElvaney NG, Doujaiji B, Moan MJ, Burnham MR, Wu MC, Crystal RG. 1993. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am Rev Respir Dis 148 (Pt 1): 1056-1060.
71. Meng QH, Springall DR, Bishop AE, Morgan K, Evans TJ, Habib S, Gruenert DC, Gyi KM, Hodson ME, Ya-coub MH, et al. 1998. Lack of inducible nitric oxide syn-thase in bronchial epithelium: A possible mechanism of susceptibility to infection in cystic fibrosis. J Pathol 184: 323-331.
72. Moss RB, Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, Gibson RL, Anderson P, Retsch-Bogart G, Nasr SZ, et al. 2005. Randomized, double-blind, placebo-controlled, dose-escalating studyof aerosolized inter-feron g-1b in patients with mild to moderate cystic fibro-sis lung disease. Pediatr Pulmonol 39: 209-218.
73. Moss RB, Mistry SJ, Konstan MW, Pilewski JM, Kerem E, Tal-Singer R, Lazaar AL, for the CF2110399 Investigators. 2012. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. J Cyst Fibros pii: S1569-1993(12)00155-5
74. Muhlebach MS, PW Stewart, Leigh MW, Noah TL. 1999. Quantitation of inflammatory response to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 160: 186-191.
75. Nichols DP, Ziady AG, Shank SL, Eastman JF, Davis PB. 2009. The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease. Am J Physiol Lung Cell Mol Physiol 297: L828-L836.
76. Noah TL, Black HR, Cheng PW, Wood RE, Leigh MW. 1997. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis 175: 638-647.
77. Oermann CM, Katz M, Wheeler C, Cumming S. 2007. A pilot studyevaluating the potential useoflow-dose meth-otrexate as an anti-inflammatory therapy for cystic fibro-sis lung disease. Pediatr Pulmonol 42 (Suppl 30): 292-293.
78. 2/2 mice. J Cell Physiol 200: 235-244.
79. Parkins MD, Rendall JC, Elborn JS. 2012. Incidence and risk factors for pulmonary exacerbation treatment failures in cystic fibrosis patients chronically infected with Pseudo-monas aeruginosa. Chest 141: 485-493.
80. Perez A, van Heeckeren AM, Nichols D, Gupta S, Eastman JF, Davis PB. 2008. Peroxisome proliferator-activated re-ceptor-g in cystic fibrosis lung epithelium. Am J Physiol Lung Cell Mol Physiol 295: L303-L313.
81. Proesmans M. 2013. Comparisonof two treatment regimens for eradication of P. aeruginosa infection in children with cystic fibrosis. J Cyst Fibros 12: 29-34.
82. Ratjen F, Munck A, Kho P, Angyalosi G, ELITE Study Group. 2010. Treatment of early Pseudomonas aeruginosa infec tion in patients with cystic fibrosis: The ELITE trial. Tho rax 65: 286-291.
83. Ren CL, Pasta DJ, Rasouliyan L, Wagener JS, Konstan MW, Morgan WJ, Scientific Advisory Group the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. 2008. Relationship between inhaled corticoste-roid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr 153: 746-751.
84. Rezaie-Majd A, Maca T, Bucek RA, Valent P, Müller MR, Husslein P, Kashanipour A, Minar E, Baghestanian M. 2002. Simvastatin reduces expression of cytokines inter-leukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholester-olemic patients. Arterioscler Thromb Vasc Biol 22: 1194-1199.
85. Ross KR, Chmiel JF, Konstan MW. 2009. The role of inhaled corticosteroids in the management of cystic fibrosis. Paediatr Drugs 11: 101-113.
86. Roum JH, Buhl R, McElvaney NG, Borok Z, Crystal RG. 1993. Systemic deficiencyof glutathione in cystic fibrosis. J Appl Physiol 75: 2419-2424.
87. Ruan H, Pownall HJ, Lodish HF. 2003. Troglitazone antagonizes tumor necrosis factor-a-induced reprogramming of adipocyte gene expression by inhibiting the transcrip-tional regulatory functions of NF-kB. J Biol Chem 278: 28181-28192.
88. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. 2010. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonaryexac-erbation. Am J Respir Crit Care Med 182: 627-632.
89. Schuster A, Haliburn C, Döring G, Goldman MH, for the Freedom Study Group. 2012. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in cystic fibrosis patients: A randomised study. Thorax 68: 344-350.
90. Smyth A, Elborn JS. 2008. Exacerbations in cystic fibrosis: 3-Management. Thorax 63: 180-184.
91. Smyth AR, Walters S. 2012. Prophylactic anti-staphylococ-cal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 12: CD001912. 23235585.
92. Stenbit AE, Flume PA. 2011. Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med 17: 442-447.
93. Taccetti G, Bianchini E, Cariani L, Buzzetti R, Costantini D, Trevisan F. 2012. Early antibiotic treatment for Pseudo-monas aeruginosa eradication in patients with cystic fi-brosis: A randomised multicentre study comparing two different protocols. Thorax 67: 853-859.
94. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. 2006. High-dose oral N-ace-tylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci 103: 4628-4633.
95. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, et al. 2011. Comparative efficacy and safetyof 4 randomized regimens to treat early Pseudomonas aerugi-nosa infection inchildren with cystic fibrosis. Arch Pediatr Adolesc Med 165: 847-856.
96. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, Muhlebach MS, Wolfgang MC, Boucher R, Gilpin DF, McDowell A, et al. 2008. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 177: 995-1001.
97. Tunney MM, Klem ER, Fodor AA, Gilpin DF, Moriarty TF, McGrath SJ, Muhlebach MS, Boucher RC, Cardwell C, Doering G, et al. 2011. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 66: 579-584.
98. Valerius NH, Koch C, Høiby N. 1991. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 338: 725-726.
99. Van Biervliet S, Devos M, Delhaye T, Van Biervliet JP, Robberecht E, Christophe A. 2008. Oral DHA supplementation in DF508 homozygous cystic fibrosis patients. Prostaglandins Leukot Essent Fatty Acids 78: 109-115.
100. Vanden Berghe W, Vermeulen L, Delerive P, De Bosscher K, Staels B, Haegeman G. 2003. A paradigm for gene regulation: Inflammation, NF-kB, and PPAR. Adv Exp Med Biol 544: 181-196.
101. VanDevanter DR, O'Riordan MA, Blumer JL, Konstan MW. 2010. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir Res 11: 137.
102. Velsor LW, van Heeckeren A, Day BJ. 2001. Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am J Physiol Lung Cell Mol Physiol 281: L31-L38.
103. Williams HD, Davies JC. 2012. Basic science for the chest physician: Pseudomonas aeruginosa and the cystic fibrosis airway. Thorax 67: 465-467.
104. Williams B, Robinette M, Slovis B, Deretci V, Perkett E.2008. Hydroxychloroquine-Pilot study of anti-inflammatory effects in cystic fibrosis. Pediatr Pulmonol 43 (Suppl 31): 314.
105. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S. 2002. Modulation of inflammatory mediators and PPARg and NFkB expression by pravastatin in response to lipopro-teins in human monocytes in vitro. Pharmacol Res 45: 147-154.
106. Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF, Cavalcoli JD, VanDevanter DR, Murray S, Li JZ, et al. 2012. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci 109: 5809-5814.
107. 12,14-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicor-bial sepsis by modulation of signal transduction pathways. J Immunol 171: 6827-6837.